Payer Value Communication Strategy

Identifying and communicating the payer value of your product’s evidence base is key to commercial success.

Global value dossiers (GVD)

We develop global value dossiers (GVDs) that clearly and concisely communicate key scientific, economic and commercial messages to HTA agencies and payers at a national, regional and local level

  • We develop global value dossiers (GVDs) that clearly and concisely communicate key scientific, economic and commercial messages to HTA agencies and payers at a national, regional and local level
  • Typically, our value dossiers use the product’s value story as the basis for structuring the evidence in an easily digestible format
  • We understand that companies have different objectives for their value dossier, including:
    • Is the GVD a comprehensive document incorporating all the evidence required for country specific HTA dossiers
    • Will the GVD provide the evidence supporting the core value story thereby enabling adaptation at a local level for HTA submissions?

Identifying payer value drivers

Identifying the payer unmet needs and disease drivers are essential to developing and successfully commercializing medical products.

  • Identifying the payer unmet needs and disease drivers are essential to developing and successfully commercializing medical products
  • We can test the payer value of your product to determine its core value drivers and payer evidence needs
  • Our experience in mapping the payer value drivers and linking them to your product’s characteristics will help to monetarise the asset’s value
  • We can help you identify the payer value drivers and understand the evidence requirements for payers and health technology assessment bodies

Value message development

We support our clients in interpreting and communicating complex clinical and economic data.

  • Value messages are the building blocks of your payer communication strategy
  • They combine the essential payer value message, along with fully reference supporting evidence to justify your claims
  • We support our clients in interpreting and communicating complex clinical and economic data in an effective way that resonates with payers
  • We will assess whether your evidence base is sufficient to support your product’s value proposition
  • Our approach to payer value message testing enables the development of a robust and validated payer value proposition

Value story testing

Our expertise in crafting concise, impactful payer value stories is critical for your successful pricing and reimbursement negotiations.

  • The payer value story (or payer value proposition) is the essential “elevator pitch” for payers, succulently communicating the products benefits
  • It brings together elements of payer unmet needs, value messages and product characteristics into on package.
  • Payer value story testing is important to enhance your payer communication strategy
  • Our expertise in crafting concise, impactful payer value stories is critical for your successful pricing and reimbursement negotiations.

Objection handler and management

Payer objection handler are a critical strategic document that capture the expected payers and HTA bodies challenges.

  • Payer objection handler are a critical strategic document that capture the expected payers and HTA bodies challenges and best practice answers
  • Coupled with payer negotiation training, this provides an essential toolkit to proactively address any issues that your product may face
  • It is an essential tool to aid your affiliates during HTA dossier development and throughout payer negotiations

Formulary access tools

Formulary access toolkits contain the essential submission information to speed access to regional and local formularies.

  • Formulary access toolkits contain the essential submission information to speed access to regional and local formularies
  • The prepopulated formulary submission templates and reference packs assists clinicians in completing funding requests, resulting in quicker regional and local access
  • Our experience in developing formulary access tools, including budget impact models and local economic evidence ensures the time to patient access is shortened

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.